viewMountain Valley MD Holdings Inc

Mountain Valley MD makes history receiving patent for their proprietary Quicksome technology

Mountain Valley MD (CSE: MVMD) Director of Life Sciences Mike Farber joined Steve Darling from Proactive with news the company has received a patent for their Quicksome Technology. This patent approval is the first for MVMD in the Canadian marketplace to pass the formal allowance stage.

Farber telling Proactive the Quicksome liposome technology utilizes an advanced two-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective oral product formats. Farber also shared with Proactive why therapeutics and not just vaccines will be the way the world needs to deal with pandemics in the future.

Quick facts: Mountain Valley MD Holdings Inc

Price: 1.35 CAD

Market: CSE
Market Cap: $378.62 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Mountain Valley MD Holdings Inc named herein, including the promotion by the Company of Mountain Valley MD Holdings Inc in any Content on the...


Mountain Valley MD proceeding with program to get FDA approval for Novel...

Mountain Valley MD (CSE: MVMD- OTCQB: MVMDF) CEO Dennis Hancock joined Steve Darling with Proactive to bring news the company has engaged the services of Camargo Pharmaceutical services to help navigate the waters of the FDA as they continue with their application for Novel Ivectosol. Hancock...

3 days, 11 hours ago

2 min read